This study aimed to evaluate the progression and treatment of experimental periodontitis (EP) in rats treated with 5-fluorouracil (5-FU).
Materials and methods
One-hundred fifty rats were divided into groups: C—control, EP—EP induction, EP/scaling and root planing (SRP)—EP induction and SRP, 5-FU—systemic treatment with 5-FU, 5-FU/EP—systemic treatment with 5-FU and EP induction, and 5-FU/EP/SRP—systemic treatment with 5-FU, EP induction and SRP. Systemic treatment consisted of the administration of 80 and 40 mg/kg of 5-FU. The animals were euthanised at 7, 15 and 30 days. Histological and immunohistochemical analyses for the detection of the receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin (OPG) and tartrate-resistant acid phosphatase (TRAP) were performed at the furcation region. A histometric analysis was performed to evaluate the percentage of bone in the furcation region (PBF).
In the 5-FU/EP and 5-FU/EP/SRP groups, there was less PBF, greater breakdown of periodontal tissues and increased immunostaining for RANKL compared with the EP and EP/SRP groups.
It can be concluded that 5-FU aggravates PE progression, impairs the host response to SRP mechanical therapy and does not seem to cause changes in the healthy periodontium.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Arias JL (2008) Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems. Molecules 13(10):2340–2369
Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3(5):330–338
Ghoshal K, Jacob ST (1994) Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Cancer Res 54(3):632–636
Santi DV, Hardy LW (1987) Catalytic mechanism and inhibition of tRNA (uracil-5-) methyltransferase: evidence for covalent catalysis. Biochemistry 26(26):8599–8606
Patton JR (1993) Ribonucleoprotein particle assembly and modification of U2 small nuclear RNA containing 5-fluorouridine. Biochemistry 32(34):8939–8944
Aherne GW, Hardcastle A, Raynaud F, Jackman AL (1996) Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Biochem Pharmacol 51(10):1293–1301
Fuse N, Doi T, Ohtsu A, Yano T, Hamamoto Y, Minashi K, Tahara M, Muto M, Asaka M, Yoshida S (2008) Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. Int J Clin Oncol 13(2):144–149
Zlotolow IM (1998) General consideration in prevention and treatment of oral manifestation of cancer therapies. In: Berget AP, Weissman DE (eds) Principles and practice of supportive oncology. Lippincott Raven, Philadelphia, p 237
Schenkein HA (2006) Host responses in maintaining periodontal health and determining periodontal disease. Periodontol 2000 40:77–93
Darveau RP (2009) The oral microbial consortium’s interaction with the periodontal innate defense system. DNA Cell Biol 28(8):389–395
Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9):1995–2025
Vanhoecke B, De Ryck T, Stringer A, Van de Wiele T, Keefe D (2014) Microbiota and their role in the pathogenesis of oral mucositis. Oral Dis. doi:10.1111/odi.12224
Ramakrishnan R, Gabrilovich DI (2013) Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother 62(3):405–410
Guchelaar HJ, Vermes I, Koopmans RP, Reutelingsperger CP, Haanen C (1998) Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Cancer Chemother Pharmacol 42(1):77–83
Tsukamoto Y, Usui M, Yamamoto G, Takagi Y, Tachikawa T, Yamamoto M, Nakamura M (2012) Role of the junctional epithelium in periodontal innate defense and homeostasis. J Periodontal Res 47(6):750–757
Djuric M, Cakic S, Hadzi-Mihailovic M, Petrovic D, Jankovic L (2010) Oral status in patients receiving 5-fluorouracil for colorectal cancer. J BUON 15(3):475–479
Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brünner N, Nauntofte B (2008) Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106(2):217–226
Mazzeo MA, Linares JA, Campos ML, Busamia BE, Dubersarsky C, Lavarda M, Jarchum G, Finkelberg AB (2009) Oral signs of intravenous chemotherapy with 5-Fluorouracil and Leucovorin calcium in colon cancer treatment. Med Oral Patol Oral Cir Bucal 14(3):E108–E113
De Almeida JM, Theodoro LH, Bosco AF, Nagata MJ, Bonfante S, Garcia VG (2008) Treatment of experimental periodontal disease by photodynamic therapy in rats with diabetes. J Periodontol 79(11):2156–2165
Garcia VG, Longo M, Gualberto Júnior EC, Bosco AF, Nagata MJ, Ervolino E, Theodoro LH (2014) Effect of the concentration of phenothiazine photosensitizers in antimicrobial photodynamic therapy on bone loss and the immune inflammatory response of induced periodontitis in rats. J Periodontal Res 49(5):584–594
Lopes NN, Plapler H, Chavantes MC, Lalla RV, Yoshimura EM, Alves MT (2009) Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols. Support Care Cancer 17(11):1409–1415
Fernandes LA, de Almeida JM, Theodoro LH, Bosco AF, Nagata MJ, Martins TM, Okamoto T, Garcia VG (2009) Treatment of experimental periodontal disease by photodynamic therapy in immunosuppressed rats. J Clin Periodontol 36(3):219–228
Feldman BF, Zinkl JG, Jain NC (2000) Schalm’s veterinary hematology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, p 1344
Branda RF, Chen Z, Brooks EM, Naud SJ, Trainer TD, McCormack JJ (2002) Diet modulates the toxicity of cancer chemotherapy in rats. J Lab Clin Med 140(5):358–368
Eisold S, Dihlmann S, Linnebacher M, Ryschich E, Aulmann M, Schmidt J, Schlehofer JR, Ridder R, von Knebel Doeberitz M (2002) Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2. Int J Cancer 100(5):606–614
Mizoguchi T, Muto A, Udagawa N, Arai, Yamashita T, Hosoya A, Ninomiya T, Nakamura H, Yamamoto Y, Kinugawa S, Nakamura M, Nakamichi Y, Kobayashi Y, Nagasawa S, Oda K, Tanaka H, Tagaya M, Penninger JM, Ito M, Takahashi N (2009) Identification of cell cycle-arrested quiescent osteoclast precursors in vivo. J Cell Biol 184(4):541–554
Nualart Grollmus ZC, Morales Chávez MC, Silvestre Donat FJ (2007) Periodontal disease associated to systemic genetic disorders. Med Oral Patol Oral Cir Bucal 12(3):E211–E215
Sallay K, Sanavi F, Ring I, Pham P, Behling UH, Nowotny A (1982) Alveolar bone destruction in the immunosuppressed rat. J Periodontal Res 17(3):263–274
Samejima Y, Ebisu S, Okada H (1990) Effect of infection with Eikenella corrodens on the progression of ligature-induced periodontitis in rats. J Periodontal Res 25(5):308–315
Sanavi F, Listgarten MA, Boyd F, Sallay K, Nowotny A (1985) The colonization and establishment of invading bacteria in periodontium of ligature-treated immunosuppressed rats. J Periodontol 56(5):273–280
Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A, Roy P (2004) Chemotherapy-induced and/or radiation therapy-induced oral mucositis—complicating the treatment of cancer. Neoplasia 6(5):423–431
Trouvin AP, Goëb V (2010) Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 5:345–354
Belibasakis GN, Bostanci N (2012) The RANKL-OPG system in clinical periodontology. J Clin Periodontol 39(3):239–248
Xian CJ, Cool JC, Pyragius T, Foster BK (2006) Damage and recovery of the bone growth mechanism in young rats following 5-fluorouracil acute chemotherapy. J Cell Biochem 99(6):1688–1704
Raghu Nadhanan R, Abimosleh SM, Su YW, Scherer MA, Howarth GS, Xian CJ (2012) Dietary emu oil supplementation suppresses 5-fluorouracil chemotherapy-induced inflammation, osteoclast formation, and bone loss. Am J Physiol Endocrinol Metab 302(11):E1440–E1449
Ogawa K, Ueno T, Kato K, Nishitani H, Akiyoshi K, Iwasa S, Nakajima TE, Hamaguchi T, Yamada Y, Hosokawa A, Sugiyama T, Shimada Y (2013) A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients. Int J Clin Oncol 18(6):1020–1024
We thank the Brazilian Federal Agency for the Support and Evaluation of Graduate Education (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—CAPES) for the scholarship and the São Paulo State Research Foundation (Fundação de Amparo à Pesquisa do Estado de São Paulo—FAPESP) for the assistance in the development of this research (FAPESP 2011/03021-3).
Conflict of interest
The authors declare that they have no conflict of interests.
Source of funding
The present study was conducted in the Periodontics Division (Department of Surgery and Integrated Clinic of Araçatuba Dental School—UNESP) supported by São Paulo State Research Foundation (Fundação de Amparo à Pesquisa do Estado de São Paulo—FAPESP 2011/03021-3).
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Garcia, V.G., Novaes, V.C.N., de Almeida, J.M. et al. Evaluation of the progression and treatment of experimental periodontitis in rats subjected to chemotherapy with 5-fluorouracil. Support Care Cancer 23, 2007–2017 (2015). https://doi.org/10.1007/s00520-014-2563-y
- Bone resorption
- Antineoplastic agents